98480576 - ACHILLES

Information

• Trademark
• 98480576

• Source

• Serial Number

  98480576

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations
  • 40 - Treatment of materials
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  April 02, 2024
  5 months ago

• Transaction Date

  September 08, 2024
  5 days ago

• Status Date

  April 02, 2024
  5 months ago

• Location Date

  September 07, 2024
  6 days ago

• Status Code

  630

• Attorney Docket Number

  60895-593482

  Attorney Name

  Rebecca Liebowitz

• Owners

  • ACHILLES THERAPEUTICS UK LIMITED

Case File Statements

• GS0401: Custom manufacture of therapeutic drugs, namely custom manufacture of cell therapies, cancer therapies, neoantigen-specific T cells, TCR-engineered T cells, cancer vaccines and neoantigen vaccines
• GS0051: Medical and veterinary preparations for therapeutic purposes; preparations for cancer therapy; antibodies; vaccines; personalised cancer vaccines; neoantigen vaccines; preparations for cell therapy; neoantigen-specific T cells; TCR-engineered T cells; preparations for modifying human or animal cells for medical or therapeutic purposes; preparations of blood extracted from humans or animals which have been adapted for medical or therapeutic purposes
• GS0441: Medical services; veterinary services; services in the extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposes; reinsertion of cells into human and animal patients; providing advice and consultancy in the field of medical and veterinary therapies; providing advice and consultancy in the field of cancer therapies and cancer vaccines
• GS0421: Scientific and technological services and research and design relating thereto; industrial analysis and research services; medical and veterinary research services including the manipulation of cells within a laboratory or research facility to enable the cells to be used for medical or therapeutic purposes; scientific research in the development of new cancer therapies, including neoantigen-specific T cells and TCR-engineered T cells; scientific research in human and animal cell therapy; scientific research into vaccines, including personalised cancer vaccines and neoantigen vaccines; scientific research into preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services

Case File Event Statements

• 4/2/2024 - 5 months ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 7/17/2024 - a month ago

  2 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI

• 9/7/2024 - 6 days ago

  3 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS